Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aim: The aim of this study is to compare the clinical outcomes of surgical resection (SR) and radiofrequency ablation (RFA) in patients with early-stage hepatocellular carcinoma (HCC) and Child-Pugh Class B liver function.

Methods: Among 7210 treatment-naïve HCC patients in our group between 2000 and 2021, this retrospective study included 41 and 456 patients who underwent SR and RFA, respectively. All included patients had Child-Pugh Class B liver function, an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2, and early-stage HCC (≤ 3 nodules, ≤ 3 cm in diameter). To adjust for baseline imbalances between the two groups, we applied inverse probability of treatment weighting (IPTW) analysis. Recurrence-free survival (RFS) and overall survival (OS) were assessed using Kaplan-Meier survival analysis and Cox regression models.

Results: Before IPTW analysis, significant differences were observed between the SR and RFA groups in Child-Pugh scores (p = 0.003), total bilirubin levels (p = 0.04), prothrombin time (p = 0.003), and the presence of ascites (p = 0.01), all of which were more favorable in the SR group. The SR group also had fewer tumors (p = 0.03) and larger tumor diameters (p = 0.002) compared to the RFA group. In the entire cohort, there were no significant differences in RFS between the two groups (p = 0.6). After IPTW analysis, the differences remained statistically nonsignificant (p = 0.4). Regarding OS, the difference was not observed between the two groups in the entire cohort (p = 0.5) and in the IPTW cohort (p = 0.9).

Conclusion: RFA appears to be as effective as SR in patients with early-stage HCC with the liver function of Child-Pugh Class B.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.17025DOI Listing

Publication Analysis

Top Keywords

child-pugh class
16
early-stage hcc
12
iptw analysis
12
surgical resection
8
resection radiofrequency
8
radiofrequency ablation
8
hcc patients
8
patients child-pugh
8
patients early-stage
8
class liver
8

Similar Publications

Central venous pressure-guided fluid management in hepatectomy under remimazolam: Impact on postoperative renal and gastrointestinal recovery.

J Gastrointest Surg

August 2025

Department of Anesthesiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address:

Background: This study aimed to evaluate the effect of central venous pressure (CVP)-guided fluid management on postoperative renal function and gastrointestinal (GI) recovery in patients with hepatocellular carcinoma (HCC) undergoing hepatectomy under remimazolam anesthesia.

Methods: This retrospective study analyzed data from 216 patients with HCC who underwent hepatectomy with remimazolam anesthesia at our hospital from January 2022 to December 2024. Patients were stratified into a CVP group (CVP-guided fluid management [n = 108]) and a control group (conventional fluid management [n = 108]).

View Article and Find Full Text PDF

It has been another active year of advances in our understanding and treatment of liver cancer. Here, we explore major research updates discovered throughout the year of 2024. Despite these significant advances, the treatment of patients with hepatocellular carcinoma (HCC) and Child-Pugh class C cirrhosis remains an unmet need.

View Article and Find Full Text PDF

Introduction: We examined whether the symptom expression of depression as assessed using the Patient Health Questionnaire-9 (PHQ-9) depression screening tool differs between patients with decompensated cirrhosis (DC) compared to primary care patients.

Methods: Study included 218 DC patients (91% Child-Pugh Class B/C) recruited from a liver transplant center and a real-world cohort of 436 outpatients from four primary care clinics in a large tertiary academic health system who completed the PHQ-9. We calculated positive screening rates for depression (PHQ-9 cutoff score of 10) for both cohorts.

View Article and Find Full Text PDF

Background & Aims: Most patients with hepatocellular carcinoma (HCC) have underlying chronic liver disease, which may influence survival outcomes. Mac-2 binding protein glycosylation isomer (M2BPGi) is a biomarker reflecting liver fibrosis status, which in turn may be associated with survival in patients with HCC treated with immune checkpoint inhibitors (ICIs), particularly in regions where viral hepatitis is endemic.

Methods: From September 2017 to September 2022, 158 patients receiving ICIs for unresectable HCC were prospectively enrolled, and baseline serum samples were collected for M2BPGi measurement.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) in patients with alcohol-related cirrhosis is commonly associated with complications such as ascites, variceal bleeding, hepatic encephalopathy, coagulopathy, and portal vein thrombosis (PVT). A significant number of patients with HCC require transjugular intrahepatic portosystemic shunt (TIPS) placement. To date, there have been no reported cases of HCC with tumor thrombus occluding a TIPS.

View Article and Find Full Text PDF